Liminatus Pharma, Inc. Warrants closed at $0.06 on Sep 23, up 37.07%, 62.5% below its highest close since May 1. Volume of 200 shares was 0.06× its 20-day average (below normal).
Split-adjusted performance: -11.4% over one month, +49.8% over six months.
Short interest was 6.6K shares at the Sep 15 settlement (114.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −3.9%, revenue growth +8.8%, net margin −231.7%, P/E 20.2×.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
